These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16488371)

  • 1. Biomarkers for the early diagnosis of Alzheimer's disease.
    de Leon MJ; Klunk W
    Lancet Neurol; 2006 Mar; 5(3):198-9. PubMed ID: 16488371
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances on biological markers in early diagnosis of Alzheimer disease.
    Padovani A; Borroni B; Di Luca M
    Adv Clin Chem; 2005; 39():107-29. PubMed ID: 16013669
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
    Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
    [No Abstract]   [Full Text] [Related]  

  • 4. Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker.
    Holtzman DM
    JAMA; 2010 Nov; 304(17):1887. PubMed ID: 21045090
    [No Abstract]   [Full Text] [Related]  

  • 5. [Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia].
    Uspenskaia OV; Iakhno NN; Belushkina NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(8):36-40. PubMed ID: 20823828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Alzheimer's indicator?
    Johns Hopkins Med Lett Health After 50; 2014 Jan; 25(13):6. PubMed ID: 24809125
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
    Dean RA; Shaw LM
    Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
    [No Abstract]   [Full Text] [Related]  

  • 8. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease.
    Papaliagkas VT; Tsolaki M; Anogianakis G
    Recent Pat CNS Drug Discov; 2010 Jun; 5(2):172-8. PubMed ID: 20408808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sharpen that needle.
    Herskovits AZ; Growdon JH
    Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
    [No Abstract]   [Full Text] [Related]  

  • 11. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
    Schmand B; Huizenga HM; van Gool WA
    Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will CSF analysis become routine in people with memory complaints?
    Gauthier S
    Lancet Neurol; 2009 Jul; 8(7):595-6. PubMed ID: 19523878
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
    Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biomarkers of Alzheimer disease].
    Rachel W; Grela A; Zyss T; Zieba A; Piekoszewski W
    Przegl Lek; 2014; 71(2):98-101. PubMed ID: 25016785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary artery bypass surgery provokes Alzheimer's disease-like changes in the cerebrospinal fluid.
    Palotás A; Reis HJ; Bogáts G; Babik B; Racsmány M; Engvau L; Kecskeméti E; Juhász A; Vieira LB; Teixeira AL; Mukhamedyarovi MA; Rizvanov AA; Yalvaç ME; Guimarães MM; Ferreira CN; Zefirov AL; Kiyasov AP; Wang L; Janka Z; Kálmán J
    J Alzheimers Dis; 2010; 21(4):1153-64. PubMed ID: 21504113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity.
    Uttner I; Schurig N; von Arnim CA; Lange-Asschenfeldt C; Brettschneider J; Riepe MW; Tumani H
    Psychiatry Res; 2011 Nov; 190(1):132-6. PubMed ID: 21620485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
    Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.